Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X7DE
|
|||
| Former ID |
DAP000042
|
|||
| Drug Name |
Nefazodone
|
|||
| Synonyms |
Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Approved | [1] | |
| Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Withdrawn from market | [2], [3] | ||
| Therapeutic Class |
Antidepressants
|
|||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H32ClN5O2
|
|||
| Canonical SMILES |
CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
|
|||
| InChI |
1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
|
|||
| InChIKey |
VRBKIVRKKCLPHA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 83366-66-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9465, 4634333, 7980102, 8152743, 14858579, 29217604, 29223544, 46508323, 48416316, 49665930, 49666410, 50057418, 50111710, 50788542, 56464118, 57322274, 85209875, 85789114, 89736110, 92309073, 93166947, 96024945, 103188221, 103963508, 104306436, 121362268, 124799827, 124893191, 125358294, 126656776, 126684012, 127339542, 127339543, 127339544, 127339545, 129514880, 131327475, 134337370, 135020756, 137001425, 142052543, 144076337, 152046617, 160964483, 163409603, 164828567, 172862753, 175268308, 175610915, 176484419
|
|||
| ChEBI ID |
CHEBI:7494
|
|||
| ADReCS Drug ID | BADD_D01546 ; BADD_D01547 | |||
| SuperDrug ATC ID |
N06AX06
|
|||
| SuperDrug CAS ID |
cas=083366669
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Nefazodone HCl (adjusted p-values: 6.63E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2C receptor (HTR2C) | Target Info | Antagonist | [5], [6] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7247). | |||
| REF 3 | Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. | |||
| REF 6 | Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.